Selected article for: "ANOVA variance and Log rank"

Author: Yakoot, Mostafa; Salem, Amel
Title: Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management of the common cold
  • Cord-id: 5byak3tw
  • Document date: 2011_1_12
  • ID: 5byak3tw
    Snippet: OBJECTIVE: To study the potential efficacy and tolerability of a natural multiherbal formula (Immumax) containing Echinacea extract 120 mg, garlic powder 100 mg, Nigella sativa oil 200 mg, and Panax ginseng extract 50 mg plus vitamin C 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the common cold. DESIGN AND SETTING: The study was conducted in a prospective, double-blind, randomized, controlled study design in an outpatient setting. PATIENTS AND METHODS: Sixty-two e
    Document: OBJECTIVE: To study the potential efficacy and tolerability of a natural multiherbal formula (Immumax) containing Echinacea extract 120 mg, garlic powder 100 mg, Nigella sativa oil 200 mg, and Panax ginseng extract 50 mg plus vitamin C 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the common cold. DESIGN AND SETTING: The study was conducted in a prospective, double-blind, randomized, controlled study design in an outpatient setting. PATIENTS AND METHODS: Sixty-two eligible patients with symptoms of the common cold were randomized to either Immumax or placebo treatment groups for the duration of their symptoms or a maximum of 14 days. Resolution rates were estimated using Kaplan–Meier analysis, and resolution profiles were compared between groups using the log-rank test. The mean percentage change in total symptom severity scores at days 4 and 8 from baseline were compared between the two groups by one-way analysis of variance (ANOVA). RESULTS: The median (interquartile range) time to resolution of all symptoms was 8 (5–9) days in the placebo group and 4 (3–6) days in the Immumax group. The results of the log-rank test indicate that symptoms resolved significantly faster in the Immumax group than in the placebo group (P < 0.001). The mean percentage reduction in total symptom severity scores from baseline at days 4 and 8 was significantly greater in the Immumax group than in the placebo group by one-way ANOVA (P < 0.01). CONCLUSION: We can conclude from our study that Immumax is helpful in reducing the duration and severity of common cold symptoms.

    Search related documents:
    Co phrase search for related documents
    • abdominal pain and acute respiratory illness: 1, 2, 3, 4, 5, 6, 7, 8
    • abdominal pain and liver renal: 1, 2, 3, 4
    • abdominal pain and low respiratory: 1, 2, 3, 4, 5, 6
    • abdominal pain and low respiratory tract: 1
    • acute illness and liver renal: 1, 2
    • acute illness and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute illness and low respiratory tract: 1, 2, 3
    • acute respiratory illness and liver renal: 1
    • acute respiratory illness and low respiratory: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory illness and low respiratory tract: 1, 2